You are here
A Look Back at the Last Decade and a Look Forward to 2020
Changes related to market forces, regulatory initiatives, and the Affordable Care Act have significantly altered the traditional work of P&T committees. Redefined issues of quality, cost, and access will become even more important in the coming years.
Drug therapy aids most epilepsy patients, but unmet challenges include drug-resistant epilepsy, adverse reactions, drug interactions, the need to better identify epileptic syndromes, and a lack of agents to prevent epilepsy and its comorbidities.
The epilepsy market’s $4.2 billion in global sales in 2012 is expected to increase to $5.4 billion by 2022. In a market crowded with products, pharmaceutical companies have shifted their focus to devising safe adjunctive therapies for refractory patients.
In these two major cardiology meetings, the pharmacology emphasis was strong on balancing risks of stroke and bleeding in treating heart attacks and atrial fibrillation.
In his exhaustively researched new book, Generic: The Unbranding of Modern Medicine, physician-historian Jeremy A. Greene, MD, PhD, explores the rise of generic drugs in the U.S. and our evolving understanding of “generic equivalence.”
Respondents Weigh In on Adherence, Vision Screenings, Patient Support Programs, and E-Prescribing
A survey on the eye care market shows areas of agreement and a few sharp differences among ophthalmologists, optometrists, and managed care executives.
Measuring mix-ups blamed for overdoses of insulin
FDA draft guidance on 503B compounding widely faulted
FDA approvals, drug indications, and updates
Naltrexone/bupropion (Contrave) for weight management; pembrolizumab (Keytruda) for melanoma; dolutegravir/abacavir/lamivudine (Triumeq) for HIV-1; and immune globulin infusion 10% (human) with recombinant human hyaluronidase (Hyqvia) for primary immunodeficiency
Riociguat (Adempas): a Novel Agent For the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Riociguat (Adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Letter to the Editor